<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1264">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318431</url>
  </required_header>
  <id_info>
    <org_study_id>COVILLE</org_study_id>
    <secondary_id>2020-A00724-35</secondary_id>
    <nct_id>NCT04318431</nct_id>
  </id_info>
  <brief_title>Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children</brief_title>
  <acronym>COVILLE</acronym>
  <official_title>Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Clinique Thérapeutique Infantile du val de Marne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is expected to provide, for the first time, data on Cov2-SARS circulation in
      asymptomatic children and children with moderate respiratory symptoms in order to construct
      the severity pyramid of this novel pathogen. This information will be essential in the coming
      weeks to understand the dynamics of the transmission of this pathogen at the population level
      and to highlight the relevance of public health interventions, particularly with regard to
      the systematic closure of schools and childcare facilities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cov2-SARS is an emerging respiratory virus of the coronavirus family responsible for a global
      epidemic since November 2019. As of March 10, 2020, it had caused more than 160,000 cases of
      corona virus disease (COVID-19), including more than 6,500 deaths worldwide. France is one of
      the main epidemic outbreaks with more than 5,000 confirmed cases and the number of diagnosed
      patients is increasing every day.

      The number of confirmed paediatric cases is relatively low, and the mortality rate in
      children is close to zero. This contrast suggests that children are more likely to present
      pauci-symptomatic or even asymptomatic forms of the disease, which are therefore undiagnosed
      in most cases. Given the rapid spread of this virus, and the fact that indigenous cases
      without an obvious chain of transmission now appear to be frequent in France, it is possible
      that the pauci-symptomatic or asymptomatic child may play a role in the transmission of the
      pathogen and the dynamics of the epidemic, as documented for other respiratory pathogens such
      as influenza. Based on this hypothesis, the closure of children's communities has been
      organized in France and other highly endemic countries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of asymptomatic children or children with mild respiratory symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of asymptomatic children or children with mild respiratory symptoms (mildly-symptomatic children) with a positive SARS-Cov2 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) on rhino pharyngeal swab or/and IgM/IgG positive serology in the Ile-de-France region during an epidemic period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Cov2-SARS cases by age</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of confirmed Cov2-SARS cases in mildly-symptomatic and asymptomatic children in different age groups (defined as 6-23 months, 2-4 years, 5-9 years, 10-15 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Cov2-SARS cases by symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of confirmed Cov2-SARS cases based on the symptoms presented by the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>14 days</time_frame>
    <description>The viral load of children with SARS-Cov2 positive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) depending on the symptoms and the age of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other respiratory viruses</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of co-infection with other respiratory viruses among children with SARS -Cov2 RT-PCR positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sars-Cov2 IgM</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of patients with Sars-Cov2 IgM +</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sars-Cov2 IgG</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of patients with Sars-Cov2 IgG +</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">605</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Data collection and rhinopharyngeal swab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After information, the collection of consent will be carried out. A clinical information sheet will be completed by the investigator in order to collect socio-demographic data, history, clinical symptoms and signs, and complementary examinations performed.
During the same consultation, a rhinopharyngeal swab will be taken for the detection of SARS -Cov2 and other respiratory pathogens by PCR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Data collection and rhinopharyngeal swab</intervention_name>
    <description>Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology</description>
    <arm_group_label>Data collection and rhinopharyngeal swab</arm_group_label>
    <other_name>IgM/IgG rapid serology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic children:

          -  Age between birth and 15 years

          -  Carrying out a visit within the framework defined by the learned societies and
             professional organisations representative of paediatrics in France, i.e. :

          -  The consultation of the first month and all consultations involving compulsory
             vaccinations (2, 4, 5, 11, 12, 16 months).

          -  Consultations for acute pathologies, infectious or not.

          -  Monitoring of chronic diseases that warrant clinical examination (the majority of
             which can be carried out by telemedicine) or in the case of acute exacerbation.

          -  In one of the participating outpatient centres

          -  During the study period

          -  With a clinical examination that does not reveal any progressive infectious pathology

        AND Pauci-symptomatic children

          -  Age between birth and 15 years,

          -  Consultant at one of the participating outpatient centres

          -  During the study period

          -  And presenting with a mild respiratory infection:

          -  Rhinopharyngitis, Acute otitis media, Angina, Bronchitis, etc.

          -  Acceptance to participate in the protocol by one of the holders of parental authority

          -  Affiliated to a social security

        Exclusion Criteria:

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cabinet du Dr Belaroussi</name>
      <address>
        <city>Boulogne</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Derkx</name>
      <address>
        <city>Champigny-sur-Marne</city>
        <zip>94500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Coicadan</name>
      <address>
        <city>Chennevières-sur-Marne</city>
        <zip>94430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>14 Av rené Samuel</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Corrard</name>
      <address>
        <city>Combs-la-Ville</city>
        <zip>77380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10 rue Delambre</name>
      <address>
        <city>Lagny-sur-Marne</city>
        <zip>77400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>157 Avenue du Général Leclerc</name>
      <address>
        <city>Maisons-Alfort</city>
        <zip>94700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21 Grande Rue Charles de Gaulle</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Deberdt</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Wollner</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 allée des Norottes</name>
      <address>
        <city>Noisy-le-Grand</city>
        <zip>93160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr D'acremont</name>
      <address>
        <city>Paris</city>
        <zip>75009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>146 Avenue Ledru Rollin</name>
      <address>
        <city>Paris</city>
        <zip>75011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>132 Boulevard du Montparnasse</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Romain</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Turberg-Romain</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>15 Quai Louis Blériot</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Michot</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>24 rue Volta</name>
      <address>
        <city>Puteaux</city>
        <zip>92800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Cohen</name>
      <address>
        <city>Saint-Maur-des-Fossés</city>
        <zip>94100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de Pédiatrie des Docteurs Ravilly et Bessa</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>13 Villa Beauséjour</name>
      <address>
        <city>Vincennes</city>
        <zip>94300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sars-Cov2 rhino-pharyngeal carriage</keyword>
  <keyword>primary care</keyword>
  <keyword>children</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

